Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes.

Thompson GR, Seed M, Naoumova RP, Neuwirth C, Walji S, Aitman TJ, Scott J, Myant NB, Soutar AK.

Atherosclerosis. 2015 Nov;243(1):328-33. doi: 10.1016/j.atherosclerosis.2015.09.029. Epub 2015 Sep 28.

2.

CDKN2B expression in adipose tissue of familial combined hyperlipidemia patients.

Horswell SD, Fryer LG, Hutchison CE, Zindrou D, Speedy HE, Town MM, Duncan EJ, Sivapackianathan R, Patel HN, Jones EL, Braithwaite A, Salm MP, Neuwirth CK, Potter E, Anderson JR, Taylor KM, Seed M, Betteridge DJ, Crook MA, Wierzbicki AS, Scott J, Naoumova RP, Shoulders CC.

J Lipid Res. 2013 Dec;54(12):3491-505. doi: 10.1194/jlr.M041814. Epub 2013 Oct 8.

3.

The origin, global distribution, and functional impact of the human 8p23 inversion polymorphism.

Salm MP, Horswell SD, Hutchison CE, Speedy HE, Yang X, Liang L, Schadt EE, Cookson WO, Wierzbicki AS, Naoumova RP, Shoulders CC.

Genome Res. 2012 Jun;22(6):1144-53. doi: 10.1101/gr.126037.111. Epub 2012 Mar 7.

4.

Quantitative 3T MR imaging of the descending thoracic aorta: patients with familial hypercholesterolemia have an increased aortic plaque burden despite long-term lipid-lowering therapy.

Schmitz SA, O'Regan DP, Fitzpatrick J, Neuwirth C, Potter E, Tosi I, Hajnal JV, Naoumova RP.

J Vasc Interv Radiol. 2008 Oct;19(10):1403-8. doi: 10.1016/j.jvir.2008.06.020. Epub 2008 Aug 9.

PMID:
18693045
5.

Liver fat content and T2*: simultaneous measurement by using breath-hold multiecho MR imaging at 3.0 T--feasibility.

O'Regan DP, Callaghan MF, Wylezinska-Arridge M, Fitzpatrick J, Naoumova RP, Hajnal JV, Schmitz SA.

Radiology. 2008 May;247(2):550-7. doi: 10.1148/radiol.2472070880. Epub 2008 Mar 18.

PMID:
18349314
6.

White matter brain lesions in midlife familial hypercholesterolemic patients at 3-Tesla magnetic resonance imaging.

Schmitz SA, O'Regan DP, Fitzpatrick J, Neuwirth C, Potter E, Tosi I, Hajnal JV, Naoumova RP.

Acta Radiol. 2008 Mar;49(2):184-9. doi: 10.1080/02841850701736263.

PMID:
18300144
7.

Cardiac T2* and lipid measurement at 3.0 T-initial experience.

O'Regan DP, Callaghan MF, Fitzpatrick J, Naoumova RP, Hajnal JV, Schmitz SA.

Eur Radiol. 2008 Apr;18(4):800-5. Epub 2007 Nov 23.

PMID:
18034347
8.

Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study.

Naoumova RP, Kindler H, Leccisotti L, Mongillo M, Khan MT, Neuwirth C, Seed M, Holvoet P, Betteridge J, Camici PG.

J Am Coll Cardiol. 2007 Nov 20;50(21):2051-8. Epub 2007 Nov 5.

9.

MRI at 3 Tesla detects no evidence for ischemic brain damage in intensively treated patients with homozygous familial hypercholesterolemia.

Schmitz SA, O'Regan DP, Fitzpatrick J, Neuwirth C, Potter E, Tosi I, Hajnal JV, Naoumova RP.

Neuroradiology. 2007 Nov;49(11):927-31. Epub 2007 Jul 21.

PMID:
17643240
10.

Pioglitazone added to conventional lipid-lowering treatment in familial combined hyperlipidaemia improves parameters of metabolic control: relation to liver, muscle and regional body fat content.

Thomas EL, Potter E, Tosi I, Fitzpatrick J, Hamilton G, Amber V, Hughes R, North C, Holvoet P, Seed M, Betteridge DJ, Bell JD, Naoumova RP.

Atherosclerosis. 2007 Nov;195(1):e181-90. Epub 2007 May 7.

PMID:
17482623
11.

Measurement of the reflectivity of the intima-medial layer of the common carotid artery improves the discriminatory value of intima-medial thickness measurement as a predictor of risk of atherosclerotic disease.

Ellis SM, Naoumova RP, Neuwirth CK, Eckersley R, Cosgrove DO, Thompson GR, Sidhu PS.

Ultrasound Med Biol. 2007 Jul;33(7):1029-38. Epub 2007 Apr 19.

PMID:
17448589
12.

Mechanisms of disease: genetic causes of familial hypercholesterolemia.

Soutar AK, Naoumova RP.

Nat Clin Pract Cardiovasc Med. 2007 Apr;4(4):214-25. Review.

PMID:
17380167
13.

Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk.

Humphries SE, Whittall RA, Hubbart CS, Maplebeck S, Cooper JA, Soutar AK, Naoumova R, Thompson GR, Seed M, Durrington PN, Miller JP, Betteridge DJ, Neil HA; Simon Broome Familial Hyperlipidaemia Register Group and Scientific Steering Committee.

J Med Genet. 2006 Dec;43(12):943-9. Erratum in: J Med Genet. 2009 Dec;46(12):861. J Med Genet. 2010 Dec;47(12):862.

15.

Therapy insight: heart disease and the insulin-resistant patient.

Cook SA, Aitman T, Naoumova RP.

Nat Clin Pract Cardiovasc Med. 2005 May;2(5):252-60. Review.

PMID:
16265509
16.

Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response.

Naoumova RP, Tosi I, Patel D, Neuwirth C, Horswell SD, Marais AD, van Heyningen C, Soutar AK.

Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2654-60. Epub 2005 Oct 13.

PMID:
16224054
17.

New prospects for lipid-lowering drugs.

Thompson GR, Naoumova RP.

Expert Opin Investig Drugs. 1998 May;7(5):715-27.

PMID:
15991963
18.

Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and apoptosis.

Wibaut-Berlaimont V, Randi AM, Mandryko V, Lunnon MW, Haskard DO, Naoumova RP.

J Thromb Haemost. 2005 Apr;3(4):677-85.

19.

A novel missense mutation in ABCA1 results in altered protein trafficking and reduced phosphatidylserine translocation in a patient with Scott syndrome.

Albrecht C, McVey JH, Elliott JI, Sardini A, Kasza I, Mumford AD, Naoumova RP, Tuddenham EG, Szabo K, Higgins CF.

Blood. 2005 Jul 15;106(2):542-9. Epub 2005 Mar 24.

20.

Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia.

Sun XM, Eden ER, Tosi I, Neuwirth CK, Wile D, Naoumova RP, Soutar AK.

Hum Mol Genet. 2005 May 1;14(9):1161-9. Epub 2005 Mar 16.

PMID:
15772090
21.

Autosomal recessive hypercholesterolemia.

Soutar AK, Naoumova RP.

Semin Vasc Med. 2004 Aug;4(3):241-8. Review.

PMID:
15630633
22.

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.

Neil HA, Seagroatt V, Betteridge DJ, Cooper MP, Durrington PN, Miller JP, Seed M, Naoumova RP, Thompson GR, Huxley R, Humphries SE.

Heart. 2004 Dec;90(12):1431-7.

23.

USF1 implicated in the aetiology of familial combined hyperlipidaemia and the metabolic syndrome.

Shoulders CC, Naoumova RP.

Trends Mol Med. 2004 Aug;10(8):362-5. Review.

PMID:
15310455
24.

Current management of severe homozygous hypercholesterolaemias.

Naoumova RP, Thompson GR, Soutar AK.

Curr Opin Lipidol. 2004 Aug;15(4):413-22. Review.

PMID:
15243214
25.

Autosomal recessive hypercholesterolaemia: long-term follow up and response to treatment.

Naoumova RP, Neuwirth C, Lee P, Miller JP, Taylor KG, Soutar AK.

Atherosclerosis. 2004 May;174(1):165-72.

PMID:
15135266
26.

Genetic diagnosis of familial hypercholesterolaemia: a mutation and a rare non-pathogenic amino acid variant in the same family.

Naoumova RP, Neuwirth C, Pottinger B, Whittal R, Humphries SE, Soutar AK.

Atherosclerosis. 2004 May;174(1):67-71.

PMID:
15135252
27.

Genetics of familial combined hyperlipidemia and risk of coronary heart disease.

Shoulders CC, Jones EL, Naoumova RP.

Hum Mol Genet. 2004 Apr 1;13 Spec No 1:R149-60. Epub 2004 Feb 5. Review.

PMID:
14764618
28.

The genes and proteins of atherogenic lipoprotein production.

Shoulders CC, Naoumova RP.

Biochem Soc Trans. 2004 Feb;32(Pt 1):70-4. Review.

PMID:
14748715
29.

Linkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia.

Eichenbaum-Voline S, Olivier M, Jones EL, Naoumova RP, Jones B, Gau B, Patel HN, Seed M, Betteridge DJ, Galton DJ, Rubin EM, Scott J, Shoulders CC, Pennacchio LA.

Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):167-74. Epub 2003 Oct 9.

30.

Confirmed locus on chromosome 11p and candidate loci on 6q and 8p for the triglyceride and cholesterol traits of combined hyperlipidemia.

Naoumova RP, Bonney SA, Eichenbaum-Voline S, Patel HN, Jones B, Jones EL, Amey J, Colilla S, Neuwirth CK, Allotey R, Seed M, Betteridge DJ, Galton DJ, Cox NJ, Bell GI, Scott J, Shoulders CC.

Arterioscler Thromb Vasc Biol. 2003 Nov 1;23(11):2070-7. Epub 2003 Sep 18.

PMID:
14500288
31.

Genetics, clinical phenotype, and molecular cell biology of autosomal recessive hypercholesterolemia.

Soutar AK, Naoumova RP, Traub LM.

Arterioscler Thromb Vasc Biol. 2003 Nov 1;23(11):1963-70. Epub 2003 Sep 4. Review.

PMID:
12958046
32.

Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders.

Jones B, Jones EL, Bonney SA, Patel HN, Mensenkamp AR, Eichenbaum-Voline S, Rudling M, Myrdal U, Annesi G, Naik S, Meadows N, Quattrone A, Islam SA, Naoumova RP, Angelin B, Infante R, Levy E, Roy CC, Freemont PS, Scott J, Shoulders CC.

Nat Genet. 2003 May;34(1):29-31.

PMID:
12692552
33.

Treatment with atorvastatin alters the ratio of interleukin-12/interleukin-10 gene expression [corrected].

Naoumova RP, Patel DD, O'Neill FH, Thompson GR, Knight BL.

Eur J Clin Invest. 2003 Jan;33(1):88-91. Erratum in: Eur J Clin Invest. 2003 Apr;33(4):359.

PMID:
12492458
34.

Restoration of LDL receptor function in cells from patients with autosomal recessive hypercholesterolemia by retroviral expression of ARH1.

Eden ER, Patel DD, Sun XM, Burden JJ, Themis M, Edwards M, Lee P, Neuwirth C, Naoumova RP, Soutar AK.

J Clin Invest. 2002 Dec;110(11):1695-702.

35.

A new drug target for treatment of dyslipidaemia associated with type 2 diabetes and the metabolic syndrome?

Naoumova RP, Betteridge DJ.

Lancet. 2002 Jun 29;359(9325):2215-6. No abstract available.

PMID:
12103282
36.

A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism.

Kong WM, Sheikh MH, Lumb PJ, Naoumova RP, Freedman DB, Crook M, Doré CJ, Finer N.

Am J Med. 2002 Apr 1;112(5):348-54. Erratum in: Am J Med 2002 Oct 1;113(5):442. Naoumova P [corrected to Naoumova Rossitza P]. Am J Med 2002 Aug 15;113(3):264.

PMID:
11904108
37.

Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia.

O'Neill FH, Patel DD, Knight BL, Neuwirth CK, Bourbon M, Soutar AK, Taylor GW, Thompson GR, Naoumova RP.

Arterioscler Thromb Vasc Biol. 2001 May;21(5):832-7.

PMID:
11348882
38.
39.

Novel lipid-regulating drugs.

Thompson GR, Naoumova RP.

Expert Opin Investig Drugs. 2000 Nov;9(11):2619-28. Review.

PMID:
11060824
40.

Characterization of a novel cellular defect in patients with phenotypic homozygous familial hypercholesterolemia.

Norman D, Sun XM, Bourbon M, Knight BL, Naoumova RP, Soutar AK.

J Clin Invest. 1999 Sep;104(5):619-28.

41.

Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men.

Riches FM, Watts GF, Hua J, Stewart GR, Naoumova RP, Barrett PH.

J Clin Endocrinol Metab. 1999 Aug;84(8):2854-61.

PMID:
10443691
42.
43.

Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia.

Rallidis L, Naoumova RP, Thompson GR, Nihoyannopoulos P.

Heart. 1998 Dec;80(6):583-90.

44.

Effects of growth hormone (GH) replacement therapy on very low density lipoprotein apolipoprotein B100 kinetics in patients with adult GH deficiency: a stable isotope study.

Christ ER, Cummings MH, Albany E, Umpleby AM, Lumb PJ, Wierzbicki AS, Naoumova RP, Boroujerdi MA, Sönksen PH, Russell-Jones DL.

J Clin Endocrinol Metab. 1999 Jan;84(1):307-16.

PMID:
9920100
45.

The effect of cholesterol reduction with fluvastatin on aortic compliance, coronary calcification and carotid intimal-medial thickness: a pilot study.

Forbat SM, Naoumova RP, Sidhu PS, Neuwirth C, MacMahon M, Thompson GR, Underwood SR.

J Cardiovasc Risk. 1998 Feb;5(1):1-10.

PMID:
9816550
46.

Cholesterol synthesis is increased in mixed hyperlipidaemia.

Naoumova RP, Kim KD, Neuwirth C, Niththyananthan S, Rendell NB, Taylor GW, Thompson GR.

Biochim Biophys Acta. 1998 Nov 2;1394(2-3):146-52.

PMID:
9795192
47.

Use of cholesterol precursors to assess changes in cholesterol synthesis under non-steady-state conditions.

Pfohl M, Naoumova RP, Kim KD, Thompson GR.

Eur J Clin Invest. 1998 Jun;28(6):491-6.

PMID:
9693942
48.

Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity.

Riches FM, Watts GF, Naoumova RP, Kelly JM, Croft KD, Thompson GR.

Int J Obes Relat Metab Disord. 1998 May;22(5):414-23.

PMID:
9622338
49.

HMG-CoA reductase is not the site of the primary defect in phytosterolemia.

Berger GM, Pegoraro RJ, Patel SB, Naidu P, Rom L, Hidaka H, Marais AD, Jadhav A, Naoumova RP, Thompson GR.

J Lipid Res. 1998 May;39(5):1046-54.

50.

Upregulation of cholesterol synthesis after acute reduction of low density lipoprotein by apheresis in normocholesterolaemic subjects: evidence for a threshold effect.

Pfohl M, Naoumova RP, Neuwirth C, Sussekov A, Smykowski J, Rendell NB, Taylor GW, Seif FJ, Thompson GR.

Atherosclerosis. 1997 Dec;135(2):257-62.

PMID:
9430376

Supplemental Content

Loading ...
Support Center